<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533427</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-367-1909</org_study_id>
    <nct_id>NCT02533427</nct_id>
  </id_info>
  <brief_title>Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol</brief_title>
  <official_title>A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed-dose
      combination (FDC) + GS-9857 on the pharmacokinetics (PK) of a representative hormonal
      contraceptive medication, norgestimate/ethinyl estradiol (Ortho Tri-Cyclen® Lo (OC)) and will
      assess the effect of norgestimate/ethinyl estradiol on the PK of SOF/VEL/GS-9857+GS-9857.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter: AUCtau for norgestimate (if possible), norelgestromin, norgestrel, and ethinyl estradiol</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Ctau for norgestimate (if possible), norelgestromin, norgestrel, and ethinyl estradiol</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Cmax of norgestimate (if possible), norelgestromin, norgestrel, and ethinyl estradiol</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>The percentage of participants experiencing any clinically significant laboratory abnormality will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax of norgestimate (if possible), norelgestromin, norgestrel, ethinyl estradiol, SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tlast of norgestimate (if possible), norelgestromin, norgestrel, ethinyl estradiol, SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast (last observed quantifiable plasma concentration of the drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: λz for norgestimate (if possible), norelgestromin, norgestrel, ethinyl estradiol, SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>λz is defined as the terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: CLss/F for norgestimate (if possible), norelgestromin, norgestrel, ethinyl estradiol, SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>CLss/F is defined as the apparent oral steady-state clearance after administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2 of norgestimate (if possible), norelgestromin, norgestrel, ethinyl estradiol, SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax of SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Ctau for SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUCtau for SOF (and its metabolites GS-566500 and GS-331007), VEL, and GS-9857 (and its metabolites if appropriate)</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>SOF/VEL/GS-9857+GS-9857</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.
Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/GS-9857 FDC plus GS-9857.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/VEL/GS-9857</intervention_name>
    <description>SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>SOF/VEL/GS-9857+GS-9857</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9857</intervention_name>
    <description>GS-9857 100 mg tablet administered orally once daily</description>
    <arm_group_label>SOF/VEL/GS-9857+GS-9857</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norgestimate/ethinyl estradiol</intervention_name>
    <description>Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert</description>
    <arm_group_label>SOF/VEL/GS-9857+GS-9857</arm_group_label>
    <other_name>Ortho-Tri-Cyclen® Lo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal female

          -  Must have a calculated BMI ≥ 19.0 and ≤ 30.0 kg/m^2 at screening

          -  Must have a negative serum pregnancy test at screening and urine pregnancy test at Day
             -1

          -  Be willing and able to comply with all study requirements.

        Exclusion Criteria:

          -  Lactating female

          -  Have a history of any of the following:

               -  Significant drug sensitivity or drug allergy (such as anaphylaxis or
                  hepatoxicity)

               -  Known hypersensitivity to the study drugs, the metabolites or formulation
                  excipients

          -  Believed, by the study investigator, to be inappropriate for study participation for
             any reason
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa Stamm, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate</mesh_term>
    <mesh_term>Norgestrel</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

